AUTHORS
Ruby Arora, MD, BA, Shaoshi Zhu2, Sebastian Lizcano3, Weiwei Ma, MS4, Zhengjia Chen, PhD5, Chen Lin, MD6, Paul Rubinstein, MD7, Carlos Galvez, MD8
AFFILIATIONS
1 University of Illinois Chicago, Chicago, Illinois, United States
2 University of Illinois Chicago, Chicago, Illinois, United States
3 University of Illinois Chicago, Chicago, Illinois, United States
4 University of Illinois Chicago, Chicago, Illinois, United States
5 University of Illinois Chicago, Chicago, Illinois, United States
6 University of Illinois Chicago, Chicago, United States
7 University of Illinois Chicago, Chicago, Illinois, United States
8 University of Illinois Chicago, Chicago, Illinois, United States
ABSTRACT
Background: Mucosa-associated lymphoid tissue (MALT) lymphoma of the nasopharynx and nasal cavity is exceedingly rare, with existing literature limited to case reports and small case series. Unlike MALT lymphomas at other sites, nasopharyngeal and nasal cavity MALT lymphomas frequently cause nasal obstruction, hearing impairment, and airway compromise, creating a distinct clinical challenge. No large-scale population-based studies have characterized the demographics, treatment patterns, or survival outcomes of this disease. We sought to provide the first comprehensive analysis of this unique subtype using the National Cancer Database (NCDB).
Methods: Patients diagnosed with MALT lymphoma (ICD-O-3 histology code 9699/3) of the nasopharynx (C110–C119) and nasal cavity (C300) between 2004 and 2022 were identified from the NCDB. Patient demographics, tumor characteristics, treatment modalities, and overall survival (OS) were analyzed. Kaplan–Meier methods were used for survival estimation, the log-rank test for subgroup comparisons, and Cox proportional hazards regression for multivariable analysis. A sensitivity analysis incorporating additional pharyngeal subsites was performed.
Results: A total of 231 patients were identified (178 nasopharynx, 53 nasal cavity). The median age was 66 years (range 40–88), with a female predominance (60.6%). The majority presented with stage I disease (53.2%). Treatment was heterogeneous: 47.6% received radiation therapy (median dose 30 Gy), 26.0% received chemotherapy, 21.2% underwent surgical resection, and 18.2% received immunotherapy. Surgery was more frequently performed for nasal cavity primaries (43.4%) than nasopharyngeal primaries (14.6%), consistent with the greater accessibility of nasal cavity tumors to surgical excision.
Temporal trends revealed a significant shift from chemotherapy (39.4% to 10.8%) to immunotherapy (7.6% to 29.7%). Radiation therapy use remained relatively stable across time (48.5% in 2004–2010, 48.7% in 2011–2016, and 48.6% in 2017–2022). In contrast, chemotherapy use declined substantially from 39.4% in 2004–2010 to 10.8% in 2017–2022 (a 73% relative reduction). Conversely, the use of immunotherapy increased nearly fourfold, from 7.6% in 2004–2010 to 29.7% in 2017–2022.
Regarding survival trends, the median OS was 163.0 months. When stratified by primary site, patients with nasal cavity MALT lymphoma demonstrated no statistically significantly different survival compared with nasopharyngeal primaries (5-year OS: 88.0% vs. 75.7%, p = 0.056). The 5-year and 10-year OS rates were 78.6% and 63.6%, respectively. No statistically significant difference in OS was observed between early-stage (I/II) and advanced-stage (III/IV) disease, consistent with the indolent biology of MALT lymphoma which has been observed in large-scale studies of MALT lymphoma at other sites. On multivariable analysis, advancing age was the only independent predictor of mortality (HR 1.07 per year, 95% CI 1.05–1.10, p < 0.001).
Treatment at academic/research facilities was associated with improved survival compared to non-academic facilities (5-year OS: 85.0% vs. 72.4%, p = 0.026). Similarly, private insurance was associated with better outcomes than other payer types (5-year OS: 85.3% vs. 74.9%, p = 0.001).
Conclusions: This study represents, to our knowledge, the largest analysis of MALT lymphoma of the nasopharynx and nasal cavity to date, leveraging the NCDB to characterize 231 patients over an 18-year period. Our findings provide several novel insights into this rare malignancy including the first population-level descriptions of treatment patterns, temporal trends, and survival outcomes. Treatment is highly heterogeneous, and the emergence of immunotherapy as a treatment alternative represents a notable paradigm shift in the era of rituximab-based regimens for extranodal marginal zone lymphoma. Age at diagnosis is the dominant prognostic factor, with each additional year of age conferring a 7% increase in mortality risk. The lack of a stage-survival association is consistent with the biology of indolent lymphomas, in which even advanced-stage disease often follows a protracted course, as observed in large-scale studies of MALT lymphoma at other sites. These findings provide a population-level evidence base to guide clinical decision-making and future prospective studies for this understudied disease.
DISCLOSURES
Ruby Arora, MD, BA: No relevant conflicts of interest to declare.